IDO1 and in situ carcinoma: To establish whether there were differences in the expression of genes for IDO and ARG in PBMCs from HCs and CIS and MS patients, relative mRNA expression (normalised to ubiquitin‐conjugating enzyme E2 D2 [UBE2D2]) was compared.